The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended a change to the terms of the Marketing Authorisation for Tagrisso (osimertinib) to include the 1st-line treatment of adult patients with locally advanced or metastatic
non-small cell lung cancer (
NSCLC).